Literature DB >> 26926646

Identification of Novel VEB β-Lactamase Enzymes and Their Impact on Avibactam Inhibition.

Sushmita D Lahiri1, Richard A Alm2.   

Abstract

Ceftazidime-avibactam has activity against Pseudomonas aeruginosa and Enterobacteriaceae expressing numerous class A and class C β-lactamases, although the ability to inhibit many minor enzyme variants has not been established. Novel VEB class A β-lactamases were identified during characterization of surveillance isolates. The cloned novel VEB β-lactamases possessed an extended-spectrum β-lactamase phenotype and were inhibited by avibactam in a concentration-dependent manner. The residues that comprised the avibactam binding pocket were either identical or functionally conserved. These data demonstrate that avibactam can inhibit VEB β-lactamases.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26926646      PMCID: PMC4862473          DOI: 10.1128/AAC.00047-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Minor extended-spectrum β-lactamases.

Authors:  Esragul Akinci; Haluk Vahaboglu
Journal:  Expert Rev Anti Infect Ther       Date:  2010-11       Impact factor: 5.091

2.  Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase.

Authors:  Jae Young Kim; Ha Il Jung; Young Jun An; Jung Hun Lee; So Jung Kim; Seok Hoon Jeong; Kye Joon Lee; Pann-Ghill Suh; Heung-Soo Lee; Sang Hee Lee; Sun-Shin Cha
Journal:  Mol Microbiol       Date:  2006-05       Impact factor: 3.501

Review 3.  Extended-spectrum beta-lactamases: structure and kinetic mechanism.

Authors:  M G P Page
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

4.  Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Authors:  S D Lahiri; M R Johnstone; P L Ross; R E McLaughlin; N B Olivier; R A Alm
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

5.  Kinetics of the interaction between avibactam and the CHE-1 class C β-lactamase.

Authors:  Adriana Fernea; Moreno Galleni; Jean-Marie Frère
Journal:  J Antimicrob Chemother       Date:  2014-10-31       Impact factor: 5.790

6.  A tripeptide deletion in the R2 loop of the class C beta-lactamase enzyme FOX-4 impairs cefoxitin hydrolysis and slightly increases susceptibility to beta-lactamase inhibitors.

Authors:  Susana Mallo; Francisco J Pérez-Llarena; Fréderic Kerff; Nelson C Soares; Moreno Galleni; Germán Bou
Journal:  J Antimicrob Chemother       Date:  2010-04-09       Impact factor: 5.790

7.  Structure of the extended-spectrum class C beta-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion.

Authors:  G V Crichlow; A P Kuzin; M Nukaga; K Mayama; T Sawai; J R Knox
Journal:  Biochemistry       Date:  1999-08-10       Impact factor: 3.162

8.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

9.  Outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital.

Authors:  Laurent Poirel; Olivier Menuteau; Nathalie Agoli; Christian Cattoen; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

10.  VEB-1-like extended-spectrum beta-lactamases in Pseudomonas aeruginosa, Kuwait.

Authors:  L Poirel; V O Rotimi; E M Mokaddas; A Karim; P Nordmann
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

View more
  9 in total

1.  Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N132G in the Conserved SDN Motif.

Authors:  Clément Ourghanlian; Daria Soroka; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

2.  Genetic Characterization of a blaVEB-2-Carrying Plasmid in Vibrio parahaemolyticus.

Authors:  Ruichao Li; Lianwei Ye; Zhiwei Zheng; Edward Wai Chi Chan; Sheng Chen
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

3.  Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.

Authors:  Sandra Mikhail; Nivedita B Singh; Razieh Kebriaei; Seth A Rice; Kyle C Stamper; Mariana Castanheira; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.

Authors:  Mazen A Sid Ahmed; Hamad Abdel Hadi; Abubaker A I Hassan; Sulieman Abu Jarir; Muna A Al-Maslamani; Nahla Omer Eltai; Khalid M Dousa; Andrea M Hujer; Ali A Sultan; Bo Soderquist; Robert A Bonomo; Emad Bashir Ibrahim; Jana Jass; Ali S Omrani
Journal:  J Antimicrob Chemother       Date:  2019-12-01       Impact factor: 5.790

5.  Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019.

Authors:  Irene Galani; Ilias Karaiskos; Maria Souli; Vassiliki Papoutsaki; Lamprini Galani; Aikaterini Gkoufa; Anastasia Antoniadou; Helen Giamarellou
Journal:  Euro Surveill       Date:  2020-01

6.  β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar.

Authors:  Mazen A Sid Ahmed; Faisal Ahmad Khan; Ali A Sultan; Bo Söderquist; Emad Bashir Ibrahim; Jana Jass; Ali S Omrani
Journal:  Antimicrob Resist Infect Control       Date:  2020-11-01       Impact factor: 4.887

7.  Whole genome sequencing of the multidrug-resistant Chryseobacterium indologenes isolated from a patient in Brazil.

Authors:  Marcelo Silva Folhas Damas; Roumayne Lopes Ferreira; Emeline Boni Campanini; Gabriela Guerrera Soares; Leslie Camelo Campos; Pedro Mendes Laprega; Andrea Soares da Costa; Caio César de Melo Freire; André Pitondo-Silva; Louise Teixeira Cerdeira; Anderson Ferreira da Cunha; Maria-Cristina da Silva Pranchevicius
Journal:  Front Med (Lausanne)       Date:  2022-07-28

8.  Evaluation of in Vitro Activity of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against ESBL-producing Enterobacterales Isolated from Intensive Care Units from Qatar.

Authors:  Mazen A Sid Ahmed; Emad Bashir Ibrahim; Jemal M Hamid; Joanne Daghfal; Mohammed A Alyazidi; Aimen H Abdelwahab; Muna A Al-Maslamani; Abdul Latif Al Khal; Hamad Abdel Hadi
Journal:  Oman Med J       Date:  2022-09-30

Review 9.  Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection.

Authors:  Mariana Castanheira; Patricia J Simner; Patricia A Bradford
Journal:  JAC Antimicrob Resist       Date:  2021-07-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.